-

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Fourth quarter 2024 webcast & conference call details

Date: 

 

Wednesday, February 19, 2025

Time: 

 

5 p.m. ET

Webcast: 

 

The live webcast can be accessed at www.exactsciences.com

Telephone: 

 

Domestic callers, dial 888-330-2384 

 

 

International callers, dial +1 240-789-2701

           

 

Access code for both domestic and international callers: 4437608

 A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Erik Holznecht
Exact Sciences Corp.
investorrelations@exactsciences.com
608-800-6605

Exact Sciences Corp.

NASDAQ:EXAS

Release Versions

Contacts

Erik Holznecht
Exact Sciences Corp.
investorrelations@exactsciences.com
608-800-6605

More News From Exact Sciences Corp.

Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW) 2025, taking place May 3-6, 2025, in San Diego, California. The abstracts demonstrate high adherence and strong predicted preference for the Cologuard® test along with abstracts on additional screening programs under development. The abstracts focused on the Cologuard test inclu...

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing. The Oncodetect test delivers clear "De...

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, “Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights,” affirms that the Oncotype DX test provides accurate and reliable information t...
Back to Newsroom